OncoMatch/Clinical Trials/NCT06824467
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Is NCT06824467 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for ovarian cancer.
Treatment: Sacituzumab tirumotecan · Bevacizumab · H1 receptor antagonist · H2 receptor antagonist · Acetaminophen (or equivalent) · Dexamethasone (or equivalent) · Steroid mouthwash (dexamethasone or equivalent) — The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Ovarian Cancer
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy — first-line
Has received 4 or more cycles of platinum-based doublet chemotherapy in first-line
Must have received: carboplatin-based chemotherapy — second-line
a total of 6 cycles of carboplatin-based doublet chemotherapy in second-line setting for ovarian cancer (OC)
Cannot have received: systemic anticancer therapy
Has received prior systemic anticancer therapy within 3 weeks or 5 half-lives (whichever is shorter) before allocation (Part 1) or randomization (Part 2)
Cannot have received: radiotherapy
Has received prior radiotherapy within 2 weeks of allocation (Part 1) or randomization (Part 2), or has radiation related toxicities, requiring corticosteroids
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham ( Site 0006) · Birmingham, Alabama
- Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0001) · New Haven, Connecticut
- Mount Sinai Cancer Center ( Site 0078) · Miami Beach, Florida
- Sarasota Memorial Hospital ( Site 0075) · Sarasota, Florida
- Florida Cancer Specialists East ( Site 7000) · West Palm Beach, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06824467 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anticancer therapy, radiotherapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages